What was studied?
Adults with diabetes inadequately controlled through diet and exercise were randomized to mazdutide or placebo for the controlled phase of a phase 3 trial.
What did the researchers report?
Glycated hemoglobin and body-weight outcomes favored mazdutide at the controlled endpoint. Diarrhea, nausea and decreased appetite were among the reported adverse events.
What are the limits?
An extension phase followed the placebo-controlled comparison. Controlled and extended observations should not be combined as if they provide the same strength of comparative evidence.
Original editorial summary by Sulan Peptide. Based on the source abstract; consult the full paper for methods, analyses, funding and disclosures.